- Author:
Tong Yang XIAO
1
;
Hai Can LIU
1
;
Xiao Qin LI
2
,
3
;
Ming Xiang HUANG
4
;
Gui Lian LI
1
;
Na LI
1
;
Yu Han YAN
2
,
3
;
Qiao LUO
5
;
Xue Zhi WANG
6
;
Ma Chao LI
1
;
Kang Lin WAN
1
Author Information
- Publication Type:Journal Article
- Keywords: Antigen; Immunologic diagnosis; Mycobacterium tuberculosis; Rv0674; Vaccine
- MeSH: Adult; Aged; Animals; Antigens, Bacterial; immunology; Female; Humans; Immunity, Cellular; Immunity, Humoral; Male; Mice; Mice, Inbred BALB C; Middle Aged; Tuberculosis; diagnosis; immunology; Young Adult
- From: Biomedical and Environmental Sciences 2019;32(6):427-437
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:This study aimed to characterize the diagnostic and vaccine potential of a novel Mycobacterium tuberculosis antigen Rv0674.
METHODS:To evaluate the diagnostic potential and antigenicity of Rv0674, IgG was evaluated using ELISA and interferon (IFN)-γ was done by using ELISpot assay among TB patients and healthy donors. For immunogenicity evaluation, BALB/c mice were immunized with Rv0674. Cytokine production was determined by cytokine release assay using an ELISA kit, and the antibodies were tested using ELISA.
RESULTS:The results of serum Elisa tests showed that Rv0674 specific immunoglobulin G (IgG) response was higher in TB patients than negative controls. And Rv0674 had good performance in serological test with sensitivity and specificity of 77.1% and 81.1%, respectively. While it shows poor sensitivity and specificity of 26.23% and 79.69% for IFN-γ tests. In BALB/c mice, Rv0674 adjuvant by DDA/Poly I:C could also induce a high level of IFN-γ, interleukin-2 and interleukin-6 as well as a high IgG titer in both high- and low-dose groups indicating that Rv0674 is essential in humoral and cellular immunity. Moreover, the cytokine profile and IgG isotype characterized Rv0674 as a Th1/Th2-mixed-type protective immunity with the predominance of Th1 cytokines.
CONCLUSION:Rv0674 may be a good potential candidate for the development of TB serological diagnosis and a new TB vaccine.